MDCX

Medicus Pharma Ltd. Common Stock

MDCX

Market cap $49.6M

Overview Fund Activity

2.41 USD

+0.16

7.11%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

2.39

-0.02

0.83%

1 day

7.11%

5 days

25.52%

1 month

7.59%

3 months

-13.62%

6 months

-26.75%

Year to date

-3.98%

1 year

-9.06%

5 years

-9.06%

10 years

-9.06%

About: Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.

Employees: 12

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

200% more funds holding

Funds holding: 6 [Q1] → 18 (+12) [Q2]

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

7.38% less ownership

Funds ownership: 22.67% [Q1] → 15.29% (-7.38%) [Q2]

45% less capital invested

Capital invested by funds: $11.3M [Q1] → $6.2M (-$5.11M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$27

1,020% upside

Avg. target

$27

1,020% upside

High target

$27

1,020% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital

Jason Kolbert

$27

Buy

Maintained

2 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about MDCX published over the past 30 days

Proactive Investors

Medicus Pharma begins Phase 2 clinical study in UAE to treat BCC

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-004 Phase 2 clinical study, a non-invasive treatment for Basal Cell Carcinoma (BCC) of the skin, has begun patient recruitment in Cleveland clinic Abu Dhabi in the United Arab Emirates (UAE). The biotech/life sciences company said the study is expected to randomize 36 patients in four sites in UAE.

Medicus Pharma begins Phase 2 clinical study in UAE to treat BCC

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that the SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin, has commenced patient recruitment in Cleveland clinic Abu Dhabi (CCAD).

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Proactive Investors

Medicus Pharma closes Antev acquisition; sees $6B market potential

Medicus Pharma (NASDAQ:MDCX) reported that it has completed its previously announced acquisition of Antev Limited, a UK-based clinical-stage drug development company. Medicus said it has acquired 98.6% of the issued and outstanding shares of Antev for total consideration of about US$2.97 million in cash plus 1,603,164 common shares of Medicus.

Medicus Pharma closes Antev acquisition; sees $6B market potential

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd.

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Proactive Investors

Medicus Pharma nears FDA milestone in cancer trial - ICYMI

Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's progress in its Phase 2 study targeting basal cell carcinoma — the most common form of skin cancer. Bokhari shared that over 75% of the 90 patients in the proof-of-concept trial have been randomized, with full enrollment expected by the end of the year.

Medicus Pharma nears FDA milestone in cancer trial - ICYMI

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has randomized more than 75% of patients Philadelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, is pleased to announce, following the acceptance of the Type C meeting request by the United States Food and Drug Administration (the "FDA"), the Company has submitted its queries in writing and expect to receive a response from the FDA before the end of Q3 2025.

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Proactive Investors

Medicus Pharma and HelixNano agree outline deal to develop heat-stable vaccines

Medicus Pharma (NASDAQ:MDCX) has agreed a non-binding memorandum of understanding with Boston-based Helix Nanotechnologies to develop a new generation of vaccines that remain stable at room temperature. The two companies plan to combine HelixNano's technology, which uses messenger ribonucleic acid (mRNA) to instruct the immune system how to fight off infectious diseases, with Medicus's method of delivering vaccines using dissolvable microneedle patches.

Medicus Pharma and HelixNano agree outline deal to develop heat-stable vaccines

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus. Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd.

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

The Company added Congresswoman Cathy McMorris Rodgers & Ajay Raju, Esq. to the Board of Directors.

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Executive Chairman & CEO of the Company to Participate in a Fireside Chat Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the scheduling of the Fireside chat of Dr. Raza Bokhari, Executive Chairman and CEO, at the BTIG Virtual Biotech Conference 2025.

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

See News Rankings

Charts implemented using Lightweight Charts™